The role of mesenchymal stem cells in liver injury

Sun, Haoyu; Shi, Chuanyin; Ye, Zhenlong; Bi, Yutie; Li, Chen; Wang, Xiaobing; Qian, Qijun

doi:10.1002/cbin.11725

Cited by 13 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EMSCs slowly shed from the scaffolds and migrated to the liver parenchyma and proliferated in the area between the scaffolds and liver parenchyma. The local microenvironment of liver injury promoted the differentiation of EMSCs into hepatocyte-like cells [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Efficiency of Nasal Mucosa-Derived Ectodermal Mesenchymal Stem Cells in Rats with Acute Hepatic Failure

Xiang

Wang

et al. 2023

Stem Cells International

View full text Add to dashboard Cite

Background. Liver transplantation is limited by the insufficiency of liver organ donors when treating end-stage liver disease or acute liver failure (ALF). Ectodermal mesenchymal stem cells (EMSCs) derived from nasal mucosa have emerged as an alternative cell-based therapy. However, the role of EMSCs in acute liver failure remains unclear. Methods. EMSCs were obtained from the nasal mucosa tissue of rats. First, EMSCs were seeded on the gelatin-chitosan scaffolds, and the biocompatibility was evaluated. Next, the protective effects of EMSCs were investigated in carbon tetrachloride- (CCl4-) induced ALF rats. Finally, we applied an indirect coculture system to analyze the paracrine effects of EMSCs on damaged hepatocytes. A three-step nontransgenic technique was performed to transform EMSCs into hepatocyte-like cells (HLCs) in vitro. Results. EMSCs exhibited a similar phenotype to other mesenchymal stem cells along with self-renewal and multilineage differentiation capabilities. EMSC-seeded gelatin-chitosan scaffolds can increase survival rates and ameliorate liver function and pathology of ALF rat models. Moreover, transplanted EMSCs can secrete paracrine factors to promote hepatocyte regeneration, targeted migration, and transdifferentiate into HLCs in response to the liver’s microenvironment, which will then repair or replace the damaged hepatocytes. Similar to mature hepatocytes, HLCs generated from EMSCs possess functions of expressing specific hepatic markers, storing glycogen, and producing urea. Conclusions. These results confirmed the feasibility of EMSCs in acute hepatic failure treatment. To our knowledge, this is the first time that EMSCs are used in the therapy of liver diseases. EMSCs are expected to be a novel and promising cell source in liver tissue engineering.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Efficiency of Nasal Mucosa-Derived Ectodermal Mesenchymal Stem Cells in Rats with Acute Hepatic Failure

Xiang

Wang

et al. 2023

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…19 IL-6 also functions as an anti-apoptotic molecule by increasing the expression of anti-apoptotic factors such as Bcl-2 and Bcl-xl during liver repair. 19,20 SDF-1 or CXCL12, is a cytokine expressed by normal liver cells. Its expression will increase in acute or chronic cell damage.…”

Section: Discussionmentioning

confidence: 99%

Phenotype and Conditioning Medium on Umbilical Cord-Mesenchymal Stem Cell (UC-MSC)

Kusnanto,

Purwanto,

Wasita

et al. 2023

InaJGHE

View full text Add to dashboard Cite

Stem cells are unspecialized cells that differentiate into more specialized cells for various tissues in the human body. Stem cells have the characteristics and ability to become themselves by performing various mitoses and differentiating different cells. Stem cells also have great potential for tissue regeneration. Detection and isolation of specific cells is very important in understanding biological processes such as development, aging, regeneration, and cell pathogenesis. Therefore, stem cells are present as an invaluable therapeutic option. Before stem cells can be applied, it is important to know the characteristics of the specific function cells or phenotypic markers. Isolation and characteristics of stem cells on culture morphology or immunotaining on specific markers. Immunohistochemistry can provide a general description of the expression of markers in a cell under certain conditions. Surface markers are the basis for identifying the characteristics and isolation of stem cells. The basic characteristics of stem cells are one that influences the outcome of the therapy to be carried out. The presence of marker cell surface expressions can also be a differentiator in searching for the origin of the stem cells used6. MSC culture method was performed with DMEM + 5% HPL. UC-MSCs with phenotype differentiation were found to be CD73+, CD90+, CD105+, Lin- while the parameters found were IL-6, SDF-1, BDNF, FGF, NGF, IL-12p70, IL-23, IL-18, IL-10 , VEGF, EGF, IL-17A, IFN-, IL-1β, PDGF, MCP-1.The results obtained are in accordance with the standard content of UC-MSC cells which can be continued as cell research.

show abstract

“…Mesenchymal stem cells (MSCs), as one of the multipotent cells, have the potential to self-renew and differentiate into multiple types of cells, such as epithelial cells or hepatocytes [ 1 , 2 ]. Studies in animal models have shown that MSC therapy can improve liver function, ameliorate liver fibrosis and reverse acute hepatic failure [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure

Wang,

Yao,

Wang

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Recent studies have shown that mesenchymal stem cell (MSC) therapy has potential therapeutic effects for patients with end-stage liver diseases. However, a consensus on the efficacy and safety of MSCs has not been reached. Methods A systemic literature review was conducted by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of MSC therapy on the outcomes among patients with end-stage liver disease. Various parameters, including pre- and post-treatment model of end-stage liver disease (MELD) score, serum albumin (ALB), total bilirubin (TB), coagulation function, aminotransferase, and survival rate, were evaluated. Results This meta-analysis included a final total of 13 studies and 854 patients. The results indicated improved liver parameters following MSC therapy at different time points, including in terms of MELD score, TB level, and ALB level, compared with conventional treatment. Furthermore, the MSC treatment increased the overall survival rate among patients with liver cirrhosis and acute-on-chronic liver failure (ACLF). The changes in transaminase level and coagulation function differed between the different therapies at various post-treatment time points, indicating that MSC therapy provided no significant benefits in this regard. The further subgroup analysis stratified by liver background revealed that patients with ACLF benefit more from MSC therapy at most time points with improved liver function, including in terms of MELD score, TB level, and ALB level. In addition, no serious side effects or adverse events were reported following MSC therapy. Conclusions The meta-analysis results suggest that MSC therapy is safe and results in improved liver function and survival rates among patients with end-stage liver disease. The subgroup analysis stratified by liver background indicated that patients with ACLF benefit more from MSC therapy than patients with liver cirrhosis at most time points.

show abstract

The role of mesenchymal stem cells in liver injury

Cited by 13 publications

References 52 publications

Therapeutic Efficiency of Nasal Mucosa-Derived Ectodermal Mesenchymal Stem Cells in Rats with Acute Hepatic Failure

Therapeutic Efficiency of Nasal Mucosa-Derived Ectodermal Mesenchymal Stem Cells in Rats with Acute Hepatic Failure

Phenotype and Conditioning Medium on Umbilical Cord-Mesenchymal Stem Cell (UC-MSC)

Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure

Contact Info

Product

Resources

About